VTGN Vistagen Therapeutics, Inc.
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline inclu…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
2 Falling Stocks Call Traders Are Targeting Today Call traders are targeting META and VTGN | ||
 Vistagen Presents Fasedienol Subgroup Data in Severe Social Anxiety Disorder Vistagen (NASDAQ:VTGN) presented exploratory clinical data for its investigational fasedienol nasal spray at Psych Congress 2026 in New Orleans on September 24, reporting findings from subgroup analyses involving participants with very severe social anxiety disorder. The findings were derived from two randomised, double-blind, placebo-controlled clinical trials and included one post-hoc analysis and one prespecified subgroup analysis. | ||
 SRX Global Acquires Stake in Vistagen Therapeutics SRX Global (AMEX:SRXH) disclosed an investment in Vistagen Therapeutics (NASDAQ:VTGN) and said it intends to engage with the company’s leadership and board on potential shareholder value initiatives. Key Investor TakeawaysSRX Global (AMEX:SRXH) acquired a stake in Vistagen Therapeutics (NASDAQ:VTGN). | ||
 Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results? We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is one of the best psychedelic stocks on our list. TheFly reported on June 30 that VTGN announced topline findings from the PALISADE-4 Phase 3 trial evaluating intranasal fasedienol for the acute treatment of social anxiety […] | ||